Mark A. Velleca - 16 Mar 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
16 Mar 2023
Net transactions value
+$18,751
Form type
4
Filing time
20 Mar 2023, 16:33:03 UTC
Previous filing
19 Dec 2022
Next filing
17 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $18,751 +11,228 +53% $1.67 32,385 16 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 16, 2023.